Entry Point Capital, LLC Adma Biologics, Inc. Call Options Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ADMA
# of Institutions
278Shares Held
179MCall Options Held
535KPut Options Held
21.2K-
Black Rock Inc. New York, NY18.6MShares$316 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.5MShares$246 Million0.0% of portfolio
-
Invesco Ltd. Atlanta, GA13.2MShares$223 Million0.03% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL8.93MShares$151 Million0.03% of portfolio
-
State Street Corp Boston, MA8.06MShares$137 Million0.0% of portfolio
About ADMA BIOLOGICS, INC.
- Ticker ADMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 196,356,992
- Market Cap $3.33B
- Description
- ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...